iRhythm Applied Sciences, Inc. (NASDAQ:IRTC), a number one digital health care options firm targeted at the growth of cardiac care, as we speak as Kevin King retires as president and CEO on January 12, 2021. Mr. King will continue to serve as an advisor to iRhythm’s board of administrators and venture. Effective that date, Mike Coyle will join as the company’s president and CEO and as a member of its board of administrators.
Under King’s management, iRhythm efficiently completed an IPO in 2016, achieving reported monetary progress and delivering considerable shareholder value. Throughout its tenure, the company’s annual revenue grew from approximately $5 million in 2011 to an analyst agreed estimate of $263 million in 2020, while its market capitalization grew from approximately $80 million to more than $5.5 billion in the same time span. Gaya.
“On behalf of iRhythm’s Board of Administrators, I would like to thank Kevin for his management and strategic contributions during his 9 years at iRhythm.
Throughout his tenure, Kevin has worked to redefine corporate strategic initiatives. Created and led the way in how cardiac arrhythmias are recognized and controlled, built a strong governance team and created great value for many stakeholders since its pre-IPO period,” said Abhijit Talwalkar, Chairman, iRhythm “Kevin’s imaginative and visionary and targeted execution has enabled the corporate to significantly deepen its presence while growing the market.
We are delighted that he will extend his position as a board member and as an advisor for a deadline. We look forward to his continued contribution to the later part of iRhythm’s progress.”
Kevin said, “I am extremely happy with everything we have done, especially with the tradition and team we have built at iRhythm and the impact our Jio service has made on the lives of over 3 million patients. I’m very happy.” King, President and CEO of iRhythm.
“While the timing of any CEO transition is rarely this simple, succession planning has been a thorough and thoughtful course. Our enterprise approach is very strong, with continued progress and ample options for expansion. I am confident that Mike’s management will continue to do so. Under this, iRhythm will continue to drive significant progress while delivering operational excellence.”
On Mr. Koel’s appointment, Talwalkar further said, “Mike is a definite leader within the healthcare business, critical in cardiology with remarkable expertise in building and scaling multi-billion greenback companies globally.
We appreciate his experience and Stay tuned for management as iRhythm progresses and enters the later part of expansion, and is confident Mike will guarantee that iRhythm will remain at the forefront of innovation, with multiple options to achieve the later stage of market management will take full advantage of.”
“This is a thrilling time in iRhythm’s history, and I am grateful for the opportunity to build on a strong foundation and lead such a large company,” said iRhythm incoming President and CEO Mike Coyle.
“Cardiac arrhythmias as a whole, and atrial fibrillation in particular, are a harmful and significantly under-diagnosed condition among sufferers worldwide. iRhythm’s extremely progressive Zio platform, in addition to its management space in AI-enabled arrhythmia detection, How these patients are recognized to allow them to receive the therapy they want can greatly enhance. I look forward to working with this skilled and well-established crew to build on the great progress options that lie ahead. I’m ready.”
Prior to becoming a member of iRhythm, Mike Coyle served as a government official at Medtronic, plc from 2009 to 2020. Throughout this era, he served as Government Vice President and Group President for Cardiovascular Group, responsible for setting the strategic curriculum and optimizing the enterprise. Medtronic’s efficiency for cardiovascular gadget companies. Prior to Medtronic, Mike offered management consulting companies to non-public equity, venture capital and medical systems technology companies from 2007 to 2009.
Prior to this, Mike served as a Circle President at St. Jude Medical, where he led. Corporate’s international pacemaker, implantable cardioverter defibrillator, and cardiac resynchronization companies. He also headed the company’s Dag Catheter division in the former chairmanship.
In addition, Mr. Coyle held certain management positions at Eli Lilly & Firm. He earned a graduate diploma from Case Western Reserve College and a graduate diploma in enterprise administration from the Wharton Faculty of Enterprise, College of Pennsylvania. He is currently serving on the Board of Administrators of the Hymonetics Company.